These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. Alban S Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163 [TBL] [Abstract][Full Text] [Related]
4. [Anticoagulant treatment of thromboses, a long term treatment]. Flessinger JN Soins; 2006 Jun; (706):36-7. PubMed ID: 16821405 [No Abstract] [Full Text] [Related]
5. Clearing the way: treating venous thromboembolism and deep vein thrombosis. Lambing A Adv Nurse Pract; 2005 Jun; 13(6):24-30; quiz 31. PubMed ID: 15984353 [No Abstract] [Full Text] [Related]
6. Heparin and angiogenesis: size matters! Rak J; Weitz JI Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):1954-5. PubMed ID: 14617616 [No Abstract] [Full Text] [Related]
7. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143 [TBL] [Abstract][Full Text] [Related]
8. Heparin and anticoagulation. Onishi A; St Ange K; Dordick JS; Linhardt RJ Front Biosci (Landmark Ed); 2016 Jun; 21(7):1372-92. PubMed ID: 27100512 [TBL] [Abstract][Full Text] [Related]
9. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
11. Changes in the USP heparin monograph and implications for clinicians. Smythe MA; Nutescu EA; Wittkowsky AK Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994 [No Abstract] [Full Text] [Related]
12. [Low-molecular-weight heparins versus unfractionated heparin for treatment of hemodialysed patients]. Kes P; Basić-Jukić N; Jurić I Lijec Vjesn; 2007; 129(8-9):305-8. PubMed ID: 18198633 [No Abstract] [Full Text] [Related]
13. Low-molecular-weight heparin for initial treatment of venous thromboembolism. Brewer D Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683 [No Abstract] [Full Text] [Related]
14. Heparins, low-molecular-weight heparins, and pentasaccharides. Dinwoodey DL; Ansell JE Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464 [TBL] [Abstract][Full Text] [Related]
15. New anticoagulant drugs: a critical perspective. Haas S Curr Hematol Rep; 2005 Sep; 4(5):335-8. PubMed ID: 16131432 [No Abstract] [Full Text] [Related]
16. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism. Rhodes S; Bond S Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458 [TBL] [Abstract][Full Text] [Related]